Last Updated : January 17, 2025
Details
Generic Name:
mirvetuximab soravtansine
Project Status:
Pending
Therapeutic Area:
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0394-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 17, 2025